Adam Elinoff will become Aglient Technologies' CFO on Nov. 17. (courtesy photo) Agilent Technologies, a supplier of laboratory medical equipment to the biotechnology industry that is based in Santa ...

ITM-11 significantly improved PFS and OS in GEP-NET patients compared to everolimus, with a favorable safety profile and higher overall response rates. Dosimetry data showed targeted tumor uptake with ...

Agilent Technologies Inc. (NYSE: A) today announced the appointment of Adam S. Elinoff as chief financial officer, effective ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...

Amgen Inc (($AMGN)) announced an update on their ongoing clinical study. Amgen Inc. is conducting a Phase 1 clinical study ...

The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the ...

Patients who depended on oral corticosteroids to care for their severe asthma experienced improvements in asthma control ...

Meanwhile, North America and Europe maintain strong market positions with mature healthcare infrastructures and established ...

Inhibrx said the encouraging results in treating the rare, slow growing cancer that often begins in the bone, bolster its plans to file a BLA in the second quarter of 2026. The company’s stock (NASDAQ ...

The preclinical drug from Vanqua Bio is designed to inhibit “C5aR1,” a part of the immune system that regulates inflammation.

However, Amgen still expects decent top-line growth for the year. Its revenue guidance of $35.5 billion at the midpoint implies a revenue increase of 6.3% compared to 2024, a respectable performance ...

The first-in-class FGFR2b antibody bemarituzumab extends overall survival in patients with advanced gastric cancer, but the ...